As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

The bombing would start at nightfall. For hours we watched what looked like giant orange and yellow fireflies streaking ...

For decades, aging has been regarded as a sign of irreversible pathologies, weakness, and dependence. Anti-aging remedies ...